Genetic testing for chemotherapy dose adjustment
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This trial checks if adjusting the dose of chemotherapy drugs 5-FU or capecitabine based on your DPYD genetic results can improve safety and effectiveness. It’s for people with cancer who are about to start these drugs for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cancer that requires treatment with 5-FU or capecitabine (either after surgery or for advanced disease).
- You have had a blood test for DPYD gene changes from a certified lab before starting chemo.
- Your DPYD test shows one specific variant (change) in one copy of the gene, or a normal result.
- You are able to perform daily activities with minimal help (ECOG score 0-2).
- You are not pregnant, not a child, and your doctor agrees the treatment is safe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
This study looks at how your genes affect the way your body handles the chemotherapy drug capecitabine when it's taken with oxaliplatin. The goal is to understand if certain genetic differences can impact drug levels, which may help personalize treatment in the future.
This trial checks how well your body processes a common chemotherapy drug (fluoropyrimidine) before you start treatment. It includes people with breast or digestive cancer, or those on dialysis, to help doctors personalize dosing and avoid severe side effects.
This trial tests whether adjusting the dose of chemotherapy drugs (5-FU or capecitabine plus oxaliplatin) based on a liver enzyme test can improve safety and effectiveness for people with gastrointestinal cancer who are starting this type of chemo for the first time.
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
This study tests whether doctors can safely find the best dose of 5-FU, a chemotherapy medicine, for people with advanced gastrointestinal cancers. The goal is to reduce side effects while still treating the cancer effectively.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.